Medicare coverage of the drugs would up federal spending by $35 billion from 2026 to 2034. Meanwhile, CNBC tests Abbott’s continuous glucose monitor Lingo.

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions of dollars, according to a new report by the Congressional Budget Office (CBO).

Medicare coverage of weight loss drugs, if authorized, is seen increasing federal spending by about $35B from 2026 to 2034. Read more.

Millions of older Americans who are dealing with obesity could soon get help from Medicare to cover the high costs of weight loss medication, which might reduce their risk of serious heart problems. However,

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034

Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some Washingtonians share how they can afford them.

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs for Medicare, but this could have a big effect on all employers health plans as well.

Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the Congressional Budget Office (CBO). In its estimates released Tuesday, CBO said 12.